Outcomes
IgA
Primary study outcomes were anti-Vi IgA antibody titers at 28 days, and both anti-Vi IgA and IgG antibody titers at 30–35 months post-vaccination. Participants with a fourfold rise in titer from baseline were considered seroconverted.